Express News | VolitionRX Ltd - Board Has Determined to Reduce Size of Board From Eight to Six Directors
ReutersApr 26 16:11 ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersImmunityBio (NASDAQ:IBRX) shares moved upwards by 32.0% to $6.52 during Tuesday's pre-market session. The company's market cap stands at $4.4 billion. Nuwellis (NASDAQ:NUWE) shares increased by
BenzingaApr 23 08:06 ET
Express News | VolitionRx Shares Are Trading Higher After the Company Announced the Availability of Its Nu.Q Vet Cancer Test in the US and Europe
Moomoo 24/7Apr 23 08:04 ET
Express News | VolitionRx Announces Its Nu.Q Vet Cancer Test Is Now Available In-Clinic Across US And Europe Through Antech
Moomoo 24/7Apr 23 08:02 ET
VolitionRX Price Target Maintained With a $2.50/Share by Cantor Fitzgerald
VolitionRX Price Target Maintained With a $2.50/Share by Cantor Fitzgerald
Dow JonesMar 27 10:05 ET
VolitionRX Is Maintained at Buy by EF Hutton
VolitionRX Is Maintained at Buy by EF Hutton
Dow JonesMar 27 09:51 ET
EF Hutton Maintains Buy on VolitionRX, Maintains $4.5 Price Target
EF Hutton analyst Tim Moore maintains VolitionRX with a Buy and maintains $4.5 price target.
Analyst UpgradesMar 27 09:43 ET
VolitionRX Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/27/2024 500.56% EF Hutton $4.5 → $4.5 Maintains Buy 01/02/2024 500.56% EF Hutton $4.5 → $4.5 Reiterates
BenzingaMar 27 09:37 ET
Benchmark Co. Sticks to Its Hold Rating for VolitionRX (VNRX)
TipRanksMar 27 08:26 ET
Earnings Call Summary | VolitionRX(VNRX.US) Q4 2023 Earnings Conference
The following is a summary of the VolitionRx Limited (VNRX) Q4 2023 Earnings Call Transcript:Financial Performance:VolitionRx recorded revenue of $775,000 for the full year 2023, a significantly highe
moomoo AIMar 26 13:12 ET · Conference Call
VolitionRX Reports FY Results
Seeking AlphaMar 26 01:52 ET
VolitionRX Q4 EPS $(0.11), Inline, Sales $243.97K Miss $450.00K Estimate
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 15.38 percent increase over losses of $(0.13) per share from the same period l
BenzingaMar 25 16:28 ET
VolitionRx Cash And Cash Equivalents As Of December 31, 2023, Totaled ~$20.7M
Financial HighlightsCash and cash equivalents as of December 31, 2023, totaled approximately $20.7 million as compared to $10.9 million as of December 31, 2022.Recorded approximately $775,000 in reven
BenzingaMar 25 16:11 ET
Press Release: VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update PR Newswire HENDERSON, Nev., March 25, 2024 Conference call to discuss financial and operational results sch
Dow JonesMar 25 16:10 ET
Earnings Scheduled For March 25, 2024
Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on revenue of $161.50 million. • Syra Health (NASDAQ:SYRA) is likely to report
BenzingaMar 25 05:33 ET
Notable Earnings After Monday's Close
Seeking AlphaMar 24 17:35 ET
Earnings Outlook For VolitionRX
VolitionRX (AMEX:VNRX) is set to give its latest quarterly earnings report on Monday, 2024-03-25. Here's what investors need to know before the announcement.Analysts estimate that VolitionRX will repo
BenzingaMar 22 10:01 ET
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 26 at 8.30 a.m. U.S. Eastern...
PR NewswireMar 21 08:30 ET
Express News | Volition And Fujifilm Vet Systems Launch Nu.Q Vet Cancer Test In Japan
Moomoo 24/7Mar 20 08:43 ET
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems...
PR NewswireMar 20 08:30 ET
No Data
No Data